Dec 19 2025 This Week in Cardiology
This Week in Cardiology
Medscape Podcasts
4.9 • 963 Ratings
🗓️ 19 December 2025
⏱️ 36 minutes
🧾️ Download transcript
Summary
The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable?
- Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361
- Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650
- UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058
II CELEBRATE Trial
- CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268
III SURPASS CVOT Trial Published
Aug 01, 2025 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1002781
- SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928
- REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link
IV FDA Pulls Andexanet Alfa From the Market
- ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051
- ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040
- Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20
V Mandrola's Top Cardiovascular Stories of 2025
https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
Transcript
Click on a timestamp to play from that location
| 0:00.0 | You're listening to This Week in Cardiology from the heart.org, Medscape Cardiology. |
| 0:05.4 | This podcast is intended for healthcare professionals only. |
| 0:08.5 | Any views expressed are the presenters own and do not necessarily reflect the views of WebMD or Medscape. |
| 0:15.0 | Hi everyone. |
| 0:16.2 | This is John Mandrola from the heart.org medscape cardiology. |
| 0:22.7 | And this is this week in cardiology for December 19th, 2025. This week, the MI paradox seen in risk scores, the celebrate trial of a new |
| 0:32.7 | subcutaneous glycoprotein 2B3A inhibitor with its interesting endpoint, the surpass CVOT trial, |
| 0:43.1 | and the bad story of Adonexit Alpha, the reversal agent for Factor 10A inhibitors. First, an announcement. |
| 0:52.9 | This week in cardiology is off for its usual two-week |
| 0:56.7 | break for the holidays. I will return on January 9th. First topic, what do risk scores mean for |
| 1:03.7 | individuals? Or, perhaps a better question, is a first, am I preventable? Cardiologist Wayne Kessmeier sent me a very interesting |
| 1:14.4 | small study that I would not have seen from Jack Advances, and I want to discuss it today. |
| 1:20.7 | The lead author, Dr. Anna Mueller and her team at the Mount Sinai Morningside Hospital in New York, |
| 1:26.9 | looked at risk scores in 465 patients |
| 1:31.3 | who were less than age 65 who had had their first MI. Their goal was to characterize |
| 1:37.3 | how well the ASCVD risk scores and symptoms reliably identify patients at risk for a first ACS events. |
| 1:46.6 | The teaser, I would say, is it not very well, actually. |
| 1:51.2 | Now, this study is elegant in its simplicity. |
| 1:54.5 | They had clinical information on 465 patients who had had their first MI. |
| 2:00.1 | They then tell us the distribution of the risk scores, |
| 2:03.0 | and I tell you, it's an eye-opener. And I think it really has some humility-inducing messages. |
| 2:09.9 | I say that because we put a lot of weight on these risk scores. Okay. For the standard ASCVD risk prediction and by pool cohort equation, the authors found that |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Medscape Podcasts, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Medscape Podcasts and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2026.